Dr. Jianming Xu
Bachelor of Clinical Medicine, Master of Oncology, PhD in Pharmacology
Professor & Director, Department of Gastrointestinal Oncology
corporate_fareFifth Medical Center, Chinese PLA General Hospital, Beijing
Jianming Xu
Bachelor of Clinical Medicine, Master of Oncology, PhD in Pharmacology
Prof. Jianming Xu is Professor and Director of Gastrointestinal Oncology at the Fifth Medical Center, Chinese PLA General Hospital, Beijing — one of China's leading tertiary oncology centres. He has dedicated more than 35 years to the clinical management and translational research of advanced digestive system cancers.
Prof. Xu's clinical work centres on gastric cancer, colorectal cancer, oesophageal cancer, hepatocellular carcinoma, pancreatic cancer, gastrointestinal stromal tumours, and neuroendocrine tumours. He is widely recognised for leadership in immunotherapy, anti-angiogenic targeted therapy, and early-phase clinical trials, and has served as principal investigator in landmark studies including ORIENT-16 and RATIONALE-306. The Chinese Anti-Cancer Association reports over 100 peer-reviewed publications in journals including The Lancet Oncology, Journal of Clinical Oncology, and Nature Communications. He has received the 8th Chinese Physician Award and the National Famous Doctor – Outstanding Achievement honour. Prof. Xu also served a two-year period as Consultant Physician at Italy's National Cancer Institute, contributing to his international academic perspective.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert gastrointestinal oncology opinion from Prof. Xu, subject to hospital availability and case acceptance.
Why Consider Prof. Jianming Xu?
Prof. Xu combines a 35-year clinical career, landmark phase III trial leadership, and more than 100 international publications to offer patients with advanced gastrointestinal cancers access to precision, evidence-based treatment strategies.
Areas of Specialisation
Advanced gastrointestinal oncology with a focus on immunotherapy, targeted therapy, and clinical trial development
Prof. Xu specialises in the full spectrum of gastrointestinal malignancies. His practice integrates modern systemic therapies — including immune checkpoint inhibitors, anti-angiogenic agents, and HER2-directed regimens — with precision biomarker-guided decision-making for each patient.
Immunotherapy & Checkpoint Inhibition
PD-1 and PD-L1 inhibitor-based regimens for gastric, oesophageal, and liver cancers.
- arrow_rightSintilimab plus chemotherapy in advanced gastric/GEJ adenocarcinoma (ORIENT-16)
- arrow_rightTislelizumab plus chemotherapy in advanced oesophageal squamous cell carcinoma (RATIONALE-306)
- arrow_rightCamrelizumab plus apatinib in advanced hepatocellular carcinoma (RESCUE trial)
- arrow_rightBiomarker-led patient selection including PD-L1 expression and MSI/MMR testing
- arrow_rightCombined checkpoint inhibitor and anti-angiogenic therapy for hepatocellular carcinoma
- arrow_rightEvaluation of treatment response and duration for eligible patients
Targeted Therapy & Precision Oncology
Molecularly guided systemic treatment for GI cancers including HER2-directed and anti-angiogenic strategies.
- arrow_rightTrastuzumab-based first-line treatment in HER2-positive gastric and GEJ adenocarcinoma
- arrow_rightEvaluation of novel HER2-targeting agents including bispecific antibody anbenitamab (KC-WISE study)
- arrow_rightSequencing decisions in HER2-positive gastric cancer following first-line progression
- arrow_rightApatinib and related anti-VEGF/VEGFR agents in advanced gastric and hepatocellular carcinoma
- arrow_rightCombination anti-angiogenic and immunotherapy strategies
- arrow_rightSurufatinib in advanced pancreatic neuroendocrine tumours (SANET-p)
- arrow_rightSurufatinib in advanced extra-pancreatic neuroendocrine tumours (SANET-ep)
- arrow_rightSystemic therapy for neuroendocrine carcinoma
Early-Phase & Emerging Therapies
Phase I and investigator-initiated studies exploring next-generation oncology treatments.
- arrow_rightInvestigator-initiated study of personalised neoantigen vaccine in advanced gastric, oesophageal, and liver cancers (ClinicalTrials.gov NCT05192460)
- arrow_rightPhase I study of NKG2D-based CAR-T therapy in advanced NKG2DL-positive solid tumours and hepatocellular carcinoma
Procedures Performed
Systemic therapy, trial-based treatment, and expert consultation for gastrointestinal cancers
Prof. Xu's practice covers the full range of medical oncology services for advanced gastrointestinal malignancies, from first-line systemic therapy through clinical trial enrolment, precision biomarker-guided planning, and expert second opinions.
Systemic Therapy for GI Cancers
Medical OncologyComprehensive chemotherapy and combined systemic treatment regimens for advanced gastrointestinal cancers.
Immunotherapy Treatment Planning
Targeted TherapyPD-1/PD-L1 inhibitor-based treatment with biomarker-driven patient selection.
Clinical Trial Participation & Enrolment
Complex DiseaseAccess to investigational therapies through active phase I, II, and III studies in gastrointestinal oncology.
Staging, Diagnostics & Biomarker Evaluation
DiagnosisMolecular and imaging-guided staging to inform personalised treatment planning.
Expert Second Opinion
Second OpinionIndependent oncology review of pathology, imaging, and treatment history for complex GI cancer cases.
Research & Publications
Over 100 international peer-reviewed publications and principal investigator roles in landmark GI oncology trials
Prof. Xu has made major contributions to gastrointestinal oncology through phase II and phase III clinical trial leadership, translational research in immunotherapy and targeted therapy, and international peer-reviewed publications. The Chinese Anti-Cancer Association reports over 100 papers in journals including The Lancet Oncology, Journal of Clinical Oncology, Science Advances, Nature Communications, and Clinical Cancer Research.
Prof. Xu leads an active clinical trial programme at the Fifth Medical Center. CancerFax can assess whether eligible patients may qualify for ongoing trials as part of the care-coordination process.
Education & Training
Prof. Xu completed his clinical medicine degree in 1988, followed by a master's degree in oncology and a PhD in pharmacology, both from the Academy of Military Medical Sciences in Beijing.
Clinical Experience
Prof. Xu has built a 35-year career in gastrointestinal oncology at the Chinese PLA General Hospital system, combining clinical leadership with an internationally active research programme. He also served as Consultant Physician at the National Cancer Institute, Italy.
Languages & International
Prof. Xu's verified consultation language is Mandarin Chinese. Language availability for international consultations should be confirmed through the hospital or CancerFax care-coordination team.
CancerFax can coordinate professional medical interpreter support for international patients seeking a consultation with Prof. Xu.
CancerFax can coordinate professional medical interpreter support for international patients requiring English or other language assistance.
How CancerFax Helps You Access Dr. Jianming Xu
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Jianming Xu's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Jianming Xu's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Jianming Xu before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Jianming Xu's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Jianming Xu's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Jianming Xu's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Jianming Xu
Prof. Xu specialises in gastrointestinal malignancies including gastric cancer, gastroesophageal junction cancer, colorectal cancer, oesophageal squamous cell carcinoma, hepatocellular carcinoma (liver cancer), pancreatic cancer, gastrointestinal stromal tumours (GIST), and neuroendocrine tumours.
Prof. Xu is Professor and Director of the Department of Gastrointestinal Oncology at the Fifth Medical Center, Chinese PLA General Hospital, Beijing — one of China's leading tertiary oncology hospitals.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Prof. Xu, subject to hospital availability and case acceptance. Direct teleconsultation availability and language support should be confirmed through the CancerFax team or the hospital's international patient department before travel planning.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review the documents, prepare the case summary, and coordinate the next steps with the hospital, subject to availability.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, molecular profiling results, imaging studies, prior treatment records, and relevant laboratory results. Prof. Xu can review advanced gastric, oesophageal, colorectal, liver, pancreatic, GIST, and neuroendocrine tumour cases. The final consultation format and timeline depend on the hospital's schedule and case acceptance.
Yes. Prof. Xu is an active clinical trial investigator and has served as Principal Investigator in landmark phase III studies including ORIENT-16 (sintilimab in gastric cancer) and RATIONALE-306 (tislelizumab in oesophageal cancer). He is also the responsible party for an investigator-initiated neoantigen vaccine study in advanced gastric, oesophageal, and liver cancers registered on ClinicalTrials.gov. CancerFax can assess trial eligibility as part of the consultation coordination process.
Yes — these are two different specialists. This page is for Prof. Jianming Xu, gastrointestinal oncologist and Director of Gastrointestinal Oncology at the Fifth Medical Center, Chinese PLA General Hospital, Beijing. Please confirm the specialist's full name when submitting your case through CancerFax.
Connect with Jianming Xu Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.